We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+12.64%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.53B
AUM Growth
+$116M
(+3.4%)
Cap. Flow
-$73.8M
Cap. Flow
% of AUM
-2.09%
Top 10 Holdings %
Top 10 Hldgs %
47.92%
Holding
99
New
17
Increased
28
Reduced
21
Closed
18
Avg Time Held Equity + Options
1.4
years
Top 10 Avg Time Held Equity + Options
1.3
years
Top 20 Avg Time Held Equity + Options
1.4
years
Avg Time Held Equity only
1.4
years
Top 10 Avg Time Held Equity only
1.3
years
Top 20 Avg Time Held Equity only
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$51.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$50.1M |
| 3 |
Amicus Therapeutics
FOLD
|
+$40.3M |
| 4 |
Centene
CNC
|
+$37.3M |
| 5 |
Stoke Therapeutics
STOK
|
+$27.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
InflaRx
IFRX
|
+$82.5M |
| 2 |
Array Biopharma Inc
ARRY
|
+$62.3M |
| 3 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$49.3M |
| 4 |
Penumbra
PEN
|
+$47.5M |
| 5 |
Xencor
XNCR
|
+$46.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.51% |
| 2 | Miscellaneous | 2.32% |
| 3 | Financials | 2.17% |
| 4 | Energy | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Establishment Labs
ESTA
$1.8B
| $220K | 0.01% |
10,000
-132,167
| -93% | -$3.16M |
2018 Q3
3 quarters
|
|
77
DELISTED
NEVRO CORP.
NVRO
| $220K | 0.01% |
3,400
| – | – |
2019 Q1
1 quarter
|
|
78
Viking Therapeutics
VKTX
$3.38B
| $135K | ﹤0.01% |
16,260
| – | – |
2018 Q3
3 quarters
|
|
|
CSLT
79
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $33K | ﹤0.01% |
10,229
| – | – |
2018 Q2
4 quarters
|
|
80
Aclaris Therapeutics
ACRS
$503M
| – | – |
-11,320
| Closed | -$68K | – |
|
81
Align Technology
ALGN
$10.3B
| – | – |
-143,200
| Closed | -$40.7M | – |
|
82
Arvinas
ARVN
$460M
| – | – |
-150,955
| Closed | -$2.23M | – |
|
83
AtriCure
ATRC
$2.95B
| – | – |
-325,000
| Closed | -$8.71M | – |
|
84
Aurinia Pharmaceuticals
AUPH
$2.26B
| – | – |
-323,265
| Closed | -$2.1M | – |
|
85
Biogen
BIIB
$34.9B
| – | – |
-165,300
| Closed | -$39.1M | – |
|
86
Cigna
CI
$78.8B
| – | – |
-1,648
| Closed | -$265K | – |
|
87
ICU Medical
ICUI
$4.16B
| – | – |
-51,721
| Closed | -$12.4M | – |
|
|
88
InflaRx
IFRX
$220M
| – | – |
-2,182,638
| Closed | -$82.5M | – |
|
|
89
Penumbra
PEN
$12.6B
| – | – |
-323,170
| Closed | -$47.5M | – |
|
90
DELISTED
Sage Therapeutics
SAGE
| – | – |
-1,450
| Closed | -$231K | – |
|
91
Surgery Partners
SGRY
$1.96B
| – | – |
-15,900
| Closed | -$179K | – |
|
92
SI-BONE Inc
SIBN
$888M
| – | – |
-538,730
| Closed | -$10.2M | – |
|
|
93
Teva Pharmaceutical Industries Limited
TEVA
$48.3B
| – | – |
-3,147,000
| Closed | -$49.3M | – |
|
94
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| – | – |
-300,000
| Closed | -$10M | – |
|
|
PRAH
95
DELISTED
PRA Health Sciences, Inc.
PRAH
| – | – |
-174,000
| Closed | -$19.2M | – |
|
|
GWPH
96
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-2,820
| Closed | -$475K | – |
|
|
HSKA
97
DELISTED
Heska Corp
HSKA
| – | – |
-226,013
| Closed | -$19.2M | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q2 2019 Portfolio in Review
As of Q2 2019, Redmile Group held 99 positions worth $3.53B, up 3.4% from $3.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Redmile Group's Q2 2019 filing shows 17 new, 28 increased, 21 reduced and 18 closed positions. Its largest new stake was Sarepta Therapeutics: 412,000 shares worth $62.6M. The largest sale was InflaRx, an estimated $82.5M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.
- Redmile Group's largest Q2 2019 buy was Sarepta Therapeutics: 412,000 shares worth $62.6M.
- Redmile Group added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $51.2M increase.
- Redmile Group's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.3M.
- Redmile Group fully exited InflaRx in Q2 2019, selling an estimated $82.5M.
- Redmile Group's ten largest holdings make up 48% of its $3.53B portfolio in Q2 2019.
- Redmile Group opened 17 new positions and closed 18 in Q2 2019.
- Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $3.53B.
Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.